Ixekizumab for treatment of psoriasis

Keyphrases

• Interleukin-17 (IL-17) 100%
• Ixekizumab 100%
• Psoriasis Treatment 100%
• Clinical Trials 40%
• Clinical Practice 20%
• Inflammatory Mediators 20%
• Recent Advances 20%
• Unknown Etiology 20%
• Monoclonal Antibody 20%
• Psoriasis 20%
• Psoriasis Pathogenesis 20%
• Chronic Inflammatory Skin Disease 20%
• Humanized 20%
• IgG4-related Disease (IgG4-RD) 20%
• Targeted Therapeutics 20%
• Homodimer 20%
• Promising Drug 20%
• IL-17 Receptor 20%
• Biological Rationale 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Psoriasis 100%
• Ixekizumab 100%
• Interleukin 17 80%
• Receptor 40%
• Clinical Trial 40%
• Monoclonal Antibody 20%
• Dermatitis 20%
• Immunoglobulin G4 20%
• Homodimer 20%

Immunology and Microbiology

• Ixekizumab 100%
• Interleukin 17 80%
• Mediator 20%
• Monoclonal Antibody 20%
• Dermatitis 20%
• Immunoglobulin G4 20%